Literature DB >> 9722889

Age and sex distributions of hematological malignancies in the U.K.

R J McNally1, D Rowland, E Roman, R A Cartwright.   

Abstract

This paper reports on an analysis of nearly 27,000 hematological malignancies diagnosed in the U.K. in the 10-year period 1984 to 1993. The unique observations provided in this analysis are the similarity of the sex-specific curves by age for acute myeloid leukemia, myelodysplasia types, polycythemia rubra vera, and myelofibrosis (or myelosclerosis). The unusual age-sex-specific distribution of essential thrombocythemia, suggesting a unique epidemiology, has never been reported before. The unusual female excess of the nodular sclerosing adolescent peak in Hodgkin's disease and its rapid fall with time is potentially of great importance. An even younger childhood peak of acute lymphoblastic leukemia is presented. Overall these data represent the most reliable available in the U.K., being population based, specially collected and will form the basis of considerable further investigations.

Entities:  

Mesh:

Year:  1997        PMID: 9722889     DOI: 10.1002/(sici)1099-1069(199711)15:4<173::aid-hon610>3.0.co;2-k

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  23 in total

Review 1.  Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisal.

Authors:  Ros Wade; Micah Rose; Aileen Rae Neilson; Lisa Stirk; Rocio Rodriguez-Lopez; David Bowen; Dawn Craig; Nerys Woolacott
Journal:  Pharmacoeconomics       Date:  2013-10       Impact factor: 4.981

2.  Ruxolitinib treatment in an infant with JAK2+ polycythaemia vera-associated Budd-Chiari syndrome.

Authors:  Mehmet Enes Coskun; Sue Height; Anil Dhawan; Nedim Hadzic
Journal:  BMJ Case Rep       Date:  2017-07-14

3.  A web tool for age-period-cohort analysis of cancer incidence and mortality rates.

Authors:  Philip S Rosenberg; David P Check; William F Anderson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-08-21       Impact factor: 4.254

4.  The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries.

Authors:  V S Hoffmann; M Baccarani; J Hasford; D Lindoerfer; S Burgstaller; D Sertic; P Costeas; J Mayer; K Indrak; H Everaus; P Koskenvesa; J Guilhot; G Schubert-Fritschle; F Castagnetti; F Di Raimondo; S Lejniece; L Griskevicius; N Thielen; T Sacha; A Hellmann; A G Turkina; A Zaritskey; A Bogdanovic; Z Sninska; I Zupan; J-L Steegmann; B Simonsson; R E Clark; A Covelli; G Guidi; R Hehlmann
Journal:  Leukemia       Date:  2015-03-18       Impact factor: 11.528

Review 5.  Polycythemia Vera.

Authors:  Jerry L Spivak
Journal:  Curr Treat Options Oncol       Date:  2018-03-07

6.  Time trends and geographical distribution of childhood leukaemia in basrah, iraq, from 2004 to 2009.

Authors:  Laith A Alrudainy; Jenan G Hassan; Hussam M Salih; Mohammed K Abbas; Athar As Majeed
Journal:  Sultan Qaboos Univ Med J       Date:  2011-05-15

Review 7.  What's all the fuss about? facts and figures about bone marrow failure and conditions.

Authors:  Sudipto Mukherjee; Mikkael A Sekeres
Journal:  Curr Hematol Malig Rep       Date:  2012-12       Impact factor: 3.952

8.  Are incidence rates of adult leukemia in the United States significantly associated with birth cohort?

Authors:  Philip S Rosenberg; Katherine L Wilson; William F Anderson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-10-12       Impact factor: 4.254

9.  Hematological malignancies in Al-amal oncology unit, aden.

Authors:  Waiel Al-Kahiry
Journal:  Indian J Hematol Blood Transfus       Date:  2011-08-18       Impact factor: 0.900

10.  Evaluation of ETV6/RUNX1 Fusion and Additional Abnormalities Involving ETV6 and/or RUNX1 Genes Using FISH Technique in Patients with Childhood Acute Lymphoblastic Leukemia.

Authors:  Cigdem Aydin; Zafer Cetin; Ayse Esra Manguoglu; Funda Tayfun; Ozden Altiok Clark; Alphan Kupesiz; Bahar Akkaya; Sibel Berker Karauzum
Journal:  Indian J Hematol Blood Transfus       Date:  2015-06-02       Impact factor: 0.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.